25.365.19 100th Legislative Session 1016
2025 South Dakota Legislature
House Bill 1016
ENROLLED
AN ACT
ENTITLED An Act to revise provisions related to pharmacy and to increase fees.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA:
Section 1. That § 13-33A-4 be AMENDED:
13-33A-4. Any school may acquire and maintain a stock of epinephrine auto -
injectors pursuant to a prescription issued by an authorized health care provider for use
in an emergency situation of a severe allergic reaction causing anaphylaxis. The provisions
of this section are not subject to the prescription requirements in chapter 36-11.
Section 2. That § 36-11-2 be AMENDED:
36-11-2. Terms used in this chapter mean:
(1) "Biological product," as defined in 42 U.S.C. § 262(i), (January 1, 2018);
(2) "Board," the State Board of Pharmacy;
(3) "Brand name," the proprietary or registered trademark name given to a drug
product by its manufacturer, labeler, or distributor and placed on the drug or on
its container, label, or wrapping at the time of packaging;
(4) "Compounding," the preparation, mixing, assembling, packaging, or labeling of a
drug or drug device as the result of a practitioner's prescription drug order or an
initiative based on the pharmacist/patient/practitioner relationship in the course of
professional practice or for the purpose of or as an incident to research, teaching,
or chemical analysis and not for sale or dispensing. The term also includes the
preparation of drug or drug devices in anticipation of prescription drug orders based
on routine, regularly observed prescribing patterns;
(5) "Delivery," the actual, constructive, or attempted transfer of a drug or drug device
from one person to another, whether or not for a consideration;
(6) "Dispensing," the preparation and delivery of a drug to a patient or a patient's
agent pursuant to a prescription drug order in a suitable container with appropriate 25.365.19 2 1016
HB1016 ENROLLED
labeling for subsequent administration to or use by a patient. The term includes
preparation of labels for drug devices if the labeling is related to the dosage and
administration of drugs;
(7) "Distributing," the delivery of a drug or drug device other than by administration
or dispensing;
(8) "Drug administration," the direct application of a drug or drug device by injection,
inhalation, ingestion, or any other means to the body of a patient or research
subject;
(9) "Drug device," equipment, process, biotechnological entity, diagnostic agent, or
other product used in combination with a drug to provide effective management of
medication regimens;
(10) "Equivalent drug product," a drug product, other than a biological product, that is
considered to be therapeutically equivalent to other pharmaceutically equivalent
products as determined by the edition of Approved Drug Products with Therapeutic
Equivalence Evaluations adopted by the board through rules promulgated pursuant
to chapter 1-26;
(11) "Interchangeable biological product," a biological product that the United States
Food and Drug Administration either has licensed and determined meets the
standards for interchangeability pursuant to 42 U.S.C. § 262(k)(4), (January 1,
2018), or has determined is therapeutically equivalent, as set forth in the edition
of Approved Drug Products with Therapeutic Equivalence Evaluations as adopted
by the board through rules promulgated pursuant to chapter 1-26;
(12) "Labeling," the process of preparing and affixing a label to any drug or drug device
container exclusive of the labeling by the manufacturer, packer, or distributor of a
nonprescription drug or commercially packaged legend drug or drug device;
(13) "Medicines," drugs or chemicals, or their preparations, in suitable form for the
prevention, relief, or cure of diseases when used either internally or externally by
man or for animals;
(14) "Nonprescription drugs," drugs that are labeled for use by the general public in
accordance with 21 U.S.C. § 352 (January 1, 2025), and may be sold without a
prescription drug order in accordance with 21 U.S.C. § 353 (January 1, 2025). The
term does not include drugs that are required by federal law to bear the statement
"Caution: federal law prohibits dispensing without prescription," drugs intended for
human use by hypodermic injection, or animal remedies regulated by chapter 39-
18; 25.365.19 3 1016
HB1016 ENROLLED
(15) "Patient counseling," oral communication by the pharmacist of information to the
patient or caregiver to improve therapy by ensuring proper use of drugs and drug
devices;
(16) "Pharmaceutical care," provision of drug therapy and other pharmaceutical patient
care services intended to achieve outcomes related to curing or preventing a
disease, eliminating or reducing a patient's symptoms, or arresting or slowing a
disease process;
(17) "Pharmacist," a person licensed by the board to engage in the practice of
pharmacy;
(18) "Pharmacy," any place of business within or outside this state where drugs are
dispensed and pharmaceutical care is provided to residents of this state;
(19) "Practitioner," a person licensed, registered, or otherwise authorized by the
jurisdiction in which the person is practicing to prescribe drugs in the course of
professional practice;
(20) "Prescription drug order," a written or oral order of a practitioner for a drug or drug
device for a specific patient;
(21) "Proper name," the nonproprietary name for a biological product designated by the
United States Food and Drug Administration license for use upon each package of
the product; and
(22) "Registered pharmacy technician," a person registered by the board who is
employed by a pharmacy to assist pharmacists in the practice of pharmacy by
performing specific tasks delegated by and under the immediate personal
supervision and control of a pharmacist, as permitted by the board.
Section 3. That § 36-11-2.1 be AMENDED:
36-11-2.1. For the purpose of this chapter, "drugs" are:
(1) Articles recognized in the official United States Pharmacopoeia or the official
National Formulary, as adopted by the board through rules promulgated pursuant
to chapter 1-26, or recognized in the official Homeopathic Pharmacopoeia of the
United States as in effect on January 1, 1993;
(2) Articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention
of disease in humans or other animals;
(3) Articles, other than food, intended to affect the structure or any functions of the
human body; and
(4) Articles intended for use as a component of any articles specified in this section. 25.365.19 4 1016
HB1016 ENROLLED
The term "drugs" excludes medical devices.
For the purposes of this section, "medical device" means an instrument, apparatus,
implement, machine, contrivance, implant, in vitro reagent, or other similar or related
article, including any component, part, or accessory, that is intended for use in the
diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention
of disease in humans or animals, or is intended to affect the structure or any function of
the body of humans or animals, that does not achieve any of its princi pal intended
purposes through chemical action within or on the body of humans or animals and that is
not dependent upon being metabolized for achievement of any of its principal intended
purposes.
Section 4. That § 36-11-5 be AMENDED:
36-11-5. The board shall hold meetings for the examination of applicants for
licensure and registration, and the transaction of other business that pertains to its duties.
Special meetings of the board may be held whenever deemed necessary by a majority of
the board. Three members of the board constitutes a quorum.
Section 5. That § 36-11-13 be AMENDED:
36-11-13. It is a Class 2 misdemeanor for any person other than a pharmacist to
engage in the practice of pharmacy, except as provided by § 36-11-14.
Section 6. That § 36-11-15 be AMENDED:
36-11-15. Any person, other than a pharmacist, who compounds or dispenses
drugs, medicines, or poisons, or who keeps a pharmacy or store for retailing or
compounding medicines, or who takes, uses, or exhibits the title of a pharmacist, is guilty
of a Class 2 misdemeanor.
Section 7. That § 36-11-16 be AMENDED:
36-11-16. The board shall issue a license to practice pharmacy to an individual
who:
(1) Submits an application prescribed by the board;
(2) Submits an application fee set by the board through rules promulgated in
accordance with chapter 1-26, but not exceeding thirty-five dollars;
(3) Is of good moral character and temperate habits; 25.365.19 5 1016
HB1016 ENROLLED
(4) Is not less than eighteen years of age;
(5) Is a graduate of a college of pharmacy recognized and approved by the board;
(6) Has had the necessary experience as determined by the board in the practice of
pharmacy under a regularly licensed pharmacist in a pharmacy where physicians'
prescriptions are compounded; and
(7) Has passed an examination prescribed by the board.
The board may allow credit for suitable military and research activities in the field
of pharmacy as part of the experience requirement.
Section 8. That § 36-11-19 be AMENDED:
36-11-19. The board may issue a license to practice pharmacy to individual who
applies to the board and submits satisfactory proof that the individual has been licensed
by examination in another state, provided that the other state required a degree of
competency at the time the individual was licensed at least equal to that required in this
state at that same time.
The board may, in determining the degree of fitness required by other states'
boards of pharmacy for granting licensure, join with other states' boards of pharmacy.
Every individual applying for licensure pursuant to this section shall pay to the board an
application fee, not to exceed one hundred fifty dollars, set by the board by rule
promulgated pursuant to chapter 1-26.
Section 9. That § 36-11-19.1 be AMENDED:
36-11-19.1. A pharmacist may:
(1) Perform drug administration pursuant to a prescription drug order;
(2) Perform drug reviews;
(3) Perform or participate in scientific or clinical drug or drug-related research as an
investigator or in collaboration with other investigators;
(4) Interpret and apply pharmacokinetic data and other pertinent laboratory data to
design safe and effective drug dosage regimens;
(5) Participate in drug and drug device selection pursuant to a prescription drug order;
(6) Initiate or modify drug therapy by protocol or other legal authority established and
approved within a licensed health care facility or by a practitioner authorized to
prescribe drugs; and
(7) Provide information on prescription drugs, which may include advising, consulting,
and educating, as necessary or as required, patients, the public, and other health 25.365.19 6 1016
HB1016 ENROLLED
care providers on the rational, safe and cost-effective use of drugs, including
therapeutic values, content, hazards and appropriate use.
The board shall establish standards for drug administration, in rules promulgated
pursuant to chapter 1-26, with the approval of a committee composed of two persons
appointed by the board, two persons appointed by the South Dakota Board of Nursing,
and two persons appointed by the State Board of Medical and Osteopathic Examiners.
Section 10. That § 36-11-19.5 be AMENDED:
36-11-19.5. Each nonresident pharmacy license expires on June thirtieth following
the date of issuance. The board shall provide a renewal application to each licensee before
June first of each year. If the licensee does not submit a renewal application, accompanied
by the renewal fee, before the expiration date, the license lapses on the date of expiration.
The board shall promulgate rules, pursuant to chapter 1-26, to establish the renewal fee,
which may not exceed two hundred dollars. If the renewal application is submitted after
the expiration of the license, the board must assess a fifty-dollar late fee and may reinstate
the license.
If a majority of ownership of a licensed nonresident pharmacy changes, the new
owners must, within thirty days after the ownership change:
(1) Submit the renewal application, indicating the change of ownership; and
(2) Pay the renewal fee established by the board as provided in this section.
Section 11. That § 36-11-19.6 be AMENDED:
36-11-19.6. The board may deny, revoke, or suspend a nonresident pharmacy
license for conduct that causes serious bodily injury or serious psychological injury to a
resident of this state, if the board has referred the matter to the regulatory or licensing
agency in the state in which the nonresident pharmacy is located and the regulatory or
licensing agency fails to initiate an investigation within forty-five days after the referral.
Any action taken to deny, revoke, or suspend a nonresident pharmacy license is a
contested case proceeding pursuant to chapter 1-26.
Section 12. That § 36-11-20 be AMENDED:
36-11-20. The board may, in compliance with chapter 1-26, suspend, revoke, or
refuse to issue or renew a license to practice pharmacy to any person who:
(1) Is guilty of a felony or a misdemeanor involving moral turpitude; 25.365.19 7 1016
HB1016 ENROLLED
(2) Is addicted to the use of alcoholic liquors or narcotic drugs to such an extent as to
render the person unfit to practice pharmacy with reasonable skill and safety;
(3) Procured a license by fraud or by false representation;
(4) Is permitting or engaging in the unauthorized sale of legend or controlled drugs or
substances; or
(5) The board finds to be in violation of any law, rule, or regulation governing
pharmacists.
Section 13. That § 36-11-23 be AMENDED:
36-11-23. To renew a license to practice pharmacy, a pharmacist must, on or
before September thirtieth of each year, submit a renewal application and pay to the board
a renewal fee set by the board in rules promulgated in accordance with chapter 1-26, not
to exceed one hundred fifty dollars. Upon application and payment of the fee, the board
shall renew the license. If a pharmacist fails to apply and pay the renewal fee, the license
expires.
The board may reinstate an expired license if the individual:
(1) Applies for reinstatement; and
(2) Pays all delinquent fees, plus a fifty-dollar late fee.
Section 14. That § 36-11-25 be AMENDED:
36-11-25. The board may issue a pharmacy intern certificate to an individual who
is gaining experience as a qualification for licensure as a pharmacist. Any pharmacy intern
issued an intern certificate shall perform the internship pursuant to rules promulgated by
the board in accordance with chapter 1-26. Nothing in this section may be construed as
giving a pharmacy intern authority to fill any prescription, except under the supervision
and in the presence of the pharmacist.
Section 15. That § 36-11-26 be AMENDED:
36-11-26. If the board is satisfied that any pharmacist is incompetent or
disqualified to perform the duties of a pharmacist pursuant to § 36-11-20 or as
contemplated by the provisions of this chapter, it may, in compliance with chapter 1-26:
(1) Issue a reprimand to the pharmacist;
(2) Place the pharmacist on probation and supervision; 25.365.19 8 1016
HB1016 ENROLLED
(3) Suspend the pharmacist's license until the pharmacist completes a course of
therapy, treatment, training, or any combination thereof;
(4) Suspend the pharmacist's license for a fixed period; and
(5) Revoke the pharmacist's license.
An individual may appeal a decision of the board as provided in chapter 1-26.
Section 16. That § 36-11-30 be AMENDED:
36-11-30. A person may not open or operate a pharmacy unless the pharmacy is
licensed by the board.
A violation of this section is a Class 2 misdemeanor. Each day of violation is a
separate offense.
Section 17. That § 36-11-31 be AMENDED:
36-11-31. Only a person that has a pharmacy license issued by the board may:
(1) Carry on, conduct, or transact business under a name that contains the term or
words "drugstore," "pharmacy," or any term implying the operation of a pharmacy;
and
(2) Advertise, describe, or refer to a place of business, in any manner, by the terms
"drugstore" or "pharmacy," or any other term or words implying the operation of
a pharmacy.
A violation of this section is a Class 2 misdemeanor.
Section 18. That § 36-11-32 be AMENDED:
36-11-32. The board shall issue a pharmacy license to a pharmacist in good
standing, if the pharmacist:
(1) Submits a form prescribed by the board; and
(2) Pays a fee, not to exceed two hundred dollars, set by the board in rules
promulgated in accordance with chapter 1-26.
Section 19. That § 36-11-33 be AMENDED:
36-11-33. The board may issue to a pharmacist in good standing a license to
operate a part-time pharmacy in a hospital, nursing facility, or related facility, provided
that the pharmacy services are limited to inpatients or residents of the facility.
The board may issue a license under this section if: 25.365.19 9 1016
HB1016 ENROLLED
(1) The pharmacist submits a form prescribed by the board and pays a fee, not to
exceed two hundred dollars, set by the board in rules promulgated in accordance
with chapter 1-26; and
(2) The merchandise and fixtures of the pharmacy are owned by a person other than
the pharmacist applying for the license.
The pharmacist must comply with the provisions of this chapter and with minimum
standards as established by the board in rules promulgated pursuant to chapter 1-26.
Section 20. That § 36-11-34 be AMENDED:
36-11-34. The board may not issue a pharmacy license to any pharmacist
applicant unless:
(1) The applicant is the owner, or part owner, of the merchandise and fixtures of the
place of business for which the pharmacy license is applied for;
(2) The application is made jointly with a pharmacist owner; or
(3) The nonpharmacist owner of the merchandise and fixtures of the place of business
for which the pharmacy license is applied for, has submitted an affidavit on a form
prescribed by the board delegating complete responsibility for the pharmaceutical
services in said place of business to the pharmacist applicant.
Section 21. That § 36-11-35 be AMENDED:
36-11-35. Each pharmacy license expires on June thirtieth following the date of
issue. To renew a pharmacy license, the pharmacist must submit a renewal application on
or before June thirtieth on a form prescribed by the board, and pay the renewal fee set
by the board in rules promulgated in accordance with chapter 1-26, but not exceeding two
hundred dollars. If the renewal application and fee is submitted after the expiration of the
license, the board must assess a fifty-dollar late fee and may reinstate the license.
If a majority ownership of the pharmacy changes, the new owners must, within
thirty days after ownership change:
(1) Submit the renewal application, indicating the change of ownership; and
(2) Pay the renewal fee established by the board as provided in this section.
Section 22. That § 36-11-36 be AMENDED:
36-11-36. Each pharmacy license issued by the board must be posted in a place
in the pharmacy that is viewable by the public. 25.365.19 10 1016
HB1016 ENROLLED
Section 23. That § 36-11-37 be AMENDED:
36-11-37. A pharmacy license may be transferred to another pharmacist,
provided an application for the transfer of the license is made upon a form prescribed by
the board and upon payment of a fifty dollar fee. The application for transfer must be filed
with the board not more than ten days after the transfer of active management is made.
If the application for transfer is received by the board after ten days, the pharmacy license
is void, and the pharmacist must reapply for the license.
Section 24. That § 36-11-38 be AMENDED:
36-11-38. In the event of the death of the pharmacist in active management, the
pharmacy license issued to the deceased under this chapter shall, within one hundred
twenty days after the date of death or on June thirtieth, whichever is sooner, become null
and void, unless the license is transferred as provided in § 36-11-37,.
Section 25. That § 36-11-39 be AMENDED:
36-11-39. The change of location of any pharmacy for which a license has been
issued from one municipality to another within this state, or the cessation of business by
the pharmacy, must be reported to the board within ten days from the occurrence on
forms prescribed by the board.
Section 26. That § 36-11-41 be AMENDED:
36-11-41. A pharmacy licensed by the board must:
(1) Be equipped with the pharmaceutical instruments and utensils prescribed by the
board in rules promulgated in accordance with chapter 1-26;
(2) Possess a stock of pharmaceuticals adequate to serve the needs of the community
in which the pharmacy is located;
(3) Have on file at all times the publications and supplements of formularies and drug
information prescribed by the board, by rules promulgated pursuant to chapter 1-
26; and
(4) Be maintained and operated in a clean and sanitary condition, free from unhealth,
foreign, or injurious contamination.
Section 27. That § 36-11-43 be AMENDED: 25.365.19 11 1016
HB1016 ENROLLED
36-11-43. The board may, in rules promulgated in accordance with chapter 1-26,
adopt a code of professional ethics for pharmacists in this state. The board shall consider
the recommendations of the South Dakota Pharmacists Association in adopting the code
or changes made thereto. The code may not contain any provision that would in any way
restrain, prohibit, or attempt to regulate the rights of any pharmacist employed in a
licensed pharmacy. Violation of the code of professional ethics may not be the basis for
criminal prosecution unless otherwise declared unlawful.
Section 28. That § 36-11-44 be AMENDED:
36-11-44. Any pharmacist who permits the compounding or dispensing of
prescriptions or the vending of drugs in the pharmacist's place of business, except under
the personal supervision of a pharmacist, or any pharmacist who, while continuing in
business, makes any false representations to procure a license for the pharmacist or any
other person, is guilty of a Class 2 misdemeanor.
Section 29. That § 36-11-48 be AMENDED:
36-11-48. The board may suspend or revoke, in accordance with chapter 1-26,
any pharmacy license issued under this chapter on the following grounds:
(1) The license was obtained by false representations made in the application therefor;
(2) The pharmacy for which the license was issued was kept open for the transaction
of business without a pharmacist in charge thereof;
(3) Conviction of a violation of any law of this state or of the United States pertaining
to the drug business or for the aiding or abetting in the violation of the law;
(4) The active management of the pharmacy was changed without the transfer, as
provided in § 36-11-37, of the license;
(5) The location of the pharmacy was changed without the change being reported as
provided in § 36-11-39;
(6) The pharmacy was kept open for the transaction of business after the pharmacist
ceased to be in active management of the pharmacy; or
(7) The minimum requirements of this chapter and the board are no longer met.
A pharmacy license may not be suspended or revoked except by a vote of three or
more members of the board.
Section 30. That § 36-11-67 be AMENDED: 25.365.19 12 1016
HB1016 ENROLLED
36-11-67. A pharmacist or physician licensed under chapter 36-4 who participates
in a drug utilization review program is not individually or jointly subject to, and is immune
from, claim, suit, liability, damages, or any other recourse, civil or criminal, arising from
any act or proceeding, decision, or determination undertaken, performed, or reached in
good faith and without malice when acting individually or jointly in carrying out the
responsibilities, authority, duties, powers, and privileges of the program conferred upon
them under any provisions of law or rule, g ood faith being presumed until proven
otherwise, with malice required to be shown by the complainant.
For the purposes of this section, a "drug utilization review program" is a program
operated solely or partially as a professional standards review organization whose purpose
is to:
(1) Educate pharmacists and practitioners on:
(a) Severe adverse reactions to drugs;
(b) Therapeutic appropriateness;
(c) Overutilization;
(d) Underutilization;
(e) Appropriate use of generic products;
(f) Therapeutic duplication;
(g) Drug-disease contraindications;
(h) Drug-drug interactions;
(i) Incorrect drug dosage or duration of drug treatment;
(j) Drug-allergy interactions; and
(k) Clinical abuse or misuse; and
(2) Identify and reduce the frequency of patterns of potential and actual fraud, abuse,
gross overuse, inappropriate care, or medically unnecessary care associated with
specific drugs or groups of drugs among practitioners, pharmacists, and patients.
Section 31. That § 36-11-72 be AMENDED:
36-11-72. The board shall promulgate rules pursuant to chapter 1-26 to provide
for the regulation of telepharmacy in this state. The rules must provide for:
(1) License and renewal application requirements, including:
(a) Establishment of an initial license fee and a renewal fee, each not to exceed
two hundred fifty dollars;
(b) Procedures for the reinstatement of an expired license; and 25.365.19 13 1016
HB1016 ENROLLED
(c) Establishment of a late fee for reinstating an expired license, not to exceed
fifty dollars;
(2) Minimum structural, security, and equipment requirements for the remote
pharmacy;
(3) Minimum staffing requirements for the central pharmacy and remote pharmacy;
(4) Record keeping requirements for the central pharmacy and remote pharmacy;
(5) Policies and procedures for the daily operation of the remote pharmacy; and
(6) Use of automated dispensing machines.
Section 32. That a NEW SECTION be added to chapter 36-11:
If the majority of ownership of a remote pharmacy changes, the new owners must,
within thirty days after the ownership change:
(1) Submit the renewal application prescribed by the board, as provided in § 36-11-
72, indicating the change of ownership; and
(2) Pay the renewal fee established by the board, as provided in § 36-11-72.
Section 33. That § 36-11A-8 be AMENDED:
36-11A-8. To apply for a wholesale or other drug distributor license, a person
must submit an application on a form provided by the board and pay an annual license
fee set by the board, not to exceed five hundred dollars.
All financial statements or related information submitted by applicants must be
treated as confidential materials.
Section 34. That § 36-11A-13 be AMENDED:
36-11A-13. Each wholesale drug distributor license expires on December thirty-
first following the date of issuance. The board shall provide an application for license
renewal to each licensee before December first of each year. To renew a license, the
licensee shall submit the renewal application and pay the annual license fee set by the
board as provided in § 36-11A-8. If application for renewal of the license accompanied by
the annual license fee is not made before the expiration date, the existing license lapses
on the date of expiration. If the board receives a renewal application and fee for an expired
license, the board must assess a fifty-dollar late fee and may reinstate the license.
If the majority of ownership of a licensed facility changes, the new owners must,
within thirty days after the ownership change: 25.365.19 14 1016
HB1016 ENROLLED
(1) Submit a renewal application, indicating the change of ownership; and
(2) Pay a fee equal to the annual license fee.
Section 35. That § 36-11-3 be REPEALED.
Section 36. That § 36-11-6 be REPEALED.
Section 37. That § 36-11-17 be REPEALED.
Section 38. That § 36-11-18 be REPEALED.
Section 39. That § 36-11-22 be REPEALED.
Section 40. That § 36-11-28 be REPEALED.
Section 41. That § 36-11-29 be REPEALED.
Section 42. That § 36-11-40 be REPEALED.
Section 43. That § 36-11-42 be REPEALED.
Section 44. That § 36-11-49 be REPEALED.
Section 45. That § 36-11A-4.2 be REPEALED.
Section 46. No later than September 30, 2025, the Board of Pharmacy shall, pursuant to
chapter 1-26, provide for and file with the secretary of state, the amendment of ARSD
20:67:02:01, as set forth below:
20:67:02:01. Application and fee. A wholesale or other distributor must
apply each year to the board, electronically or on a form supplied by the board, for a
license to engage in the distribution of prescription drugs. Each application must be
accompanied by a license fee of five hundred dollars.
Source: 18 SDR 95, effective November 25, 1991; 24 SDR 160, effective May
26, 1998; 45 SDR 86, effective December 24, 2018.
General Authority: SDCL 36-11A-14.
Law Implemented: SDCL 36-11A-7, 36-11A-8. 25.365.19 15 1016
HB1016 ENROLLED
An Act to revise provisions related to pharmacy and to increase fees.
I certify that the attached Act originated in
the:
House as Bill No. 1016
Chief Clerk
Speaker of the House
Attest:
Chief Clerk
President of the Senate
Attest:
Secretary of the Senate
House Bill No. 1016
File No. ____
Chapter No. ______
Received at this Executive Office
this _____ day of _____________,
2025 at ____________M.
By
for the Governor
The attached Act is hereby
approved this ________ day of
______________, A.D., 2025
Governor
STATE OF SOUTH DAKOTA ,
ss.
Office of the Secretary of State
Filed ____________, 2025
at _________ o'clock __M.
Secretary of State
By
Asst. Secretary of State